Please login to the form below

Not currently logged in

Roche buys Memory Pharmaceuticals for $50m

Roche has signed a deal to acquire biopharmaceutical company Memory in a cash deal worth around $50m

Roche has signed a deal to acquire biopharmaceutical company Memory in a cash deal worth around $50m.

Memory develops drugs for central nervous system (CNS) disorders such as Alzheimer's and schizophrenia. The company currently has drug candidates in these areas undergoing clinical trials in partnership with Roche.

"Acquiring Memory will enable Roche to secure the future development of its promising nicotinic alpha-7 agonists," said William Burns, CEO Division Roche Pharmaceuticals. "The innovative work carried out by the scientists at Memory will be fully integrated into Roche's R&D portfolio with the aim of providing new hope for patients and caregivers affected by devastating diseases such as Alzheimer's."

Jonathan Fleming, chairman of the board of directors of Memory said: "Since founding Memory in 1998, we have focused on developing medicines that could make a real difference to the lives of CNS patients. I am proud of the progress our dedicated team has made and I am confident that Roche's capabilities and experience in the CNS field will enable our research to realise its full potential."

Under the terms of the merger agreement, Roche will tender an offer to acquire all outstanding shares of Memory at a 319 per cent premium to their closing price on November 24, 2008. The closing of the tender is subject to Roche holding a majority share once its acquired shares are added to its existing shares.

25th November 2008


Featured jobs

Subscribe to our email news alerts


Add my company

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...